Little House Capital LLC Has $967,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Little House Capital LLC raised its position in shares of Pfizer Inc. (NYSE:PFE) by 9.3% in the first quarter, according to its most recent filing with the SEC. The firm owned 34,850 shares of the biopharmaceutical company’s stock after purchasing an additional 2,976 shares during the quarter. Little House Capital LLC’s holdings in Pfizer were worth $967,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. GoalVest Advisory LLC boosted its position in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares in the last quarter. Creekmur Asset Management LLC bought a new stake in shares of Pfizer in the 4th quarter valued at $32,000. Trivant Custom Portfolio Group LLC lifted its position in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares during the period. VisionPoint Advisory Group LLC boosted its stake in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new stake in Pfizer in the fourth quarter valued at $36,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

NYSE:PFE traded up $0.22 during trading on Monday, reaching $28.20. The company’s stock had a trading volume of 16,859,004 shares, compared to its average volume of 40,716,523. The firm has a market cap of $159.80 billion, a price-to-earnings ratio of -470.42, a price-to-earnings-growth ratio of 1.10 and a beta of 0.69. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $37.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The firm has a 50 day moving average of $27.90 and a 200-day moving average of $27.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter last year, the company posted $1.23 earnings per share. The firm’s quarterly revenue was down 19.5% compared to the same quarter last year. Research analysts expect that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.96%. The ex-dividend date is Thursday, July 25th. Pfizer’s dividend payout ratio is currently -2,799.53%.

Wall Street Analyst Weigh In

PFE has been the subject of several research reports. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, June 26th. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Morgan Stanley upped their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $35.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.